Lexaria Bioscience Corp (LEXX)

Etorro trading 970x250
Lexaria Bioscience Corp (LEXX) Logo

About Lexaria Bioscience Corp

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada. Address: 100 ? 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7

Lexaria Bioscience Corp News and around…

Latest news about Lexaria Bioscience Corp (LEXX) common stock and company :

Companies Like Lexaria Bioscience (NASDAQ:LEXX) Are In A Position To Invest In Growth
01 Dec, 2021 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Lexaria's DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study
29 Nov, 2021 FinancialContent

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently conducted a study on canines in collaboration with an independent testing ...

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study
24 Nov, 2021 FinancialContent
Lexaria Bioscience's DehydraTECH(TM) Drug Delivery Tech Finding Multiple Applications
24 Nov, 2021 FinancialContent

Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursues regulatory approval for ...

Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Drug Delivery Technology Finding Multiple Medical Applications
24 Nov, 2021 FinancialContent
Lexaria Bioscience Announces 2022 DehydraTECH(TM) R&D Programs
18 Nov, 2021 FinancialContent

Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and ...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes
18 Nov, 2021 FinancialContent
Lexaria Bioscience Corp. Embarks on Ambitious Hypertension Clinical Study
15 Nov, 2021 FinancialContent

Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and its most ambitious yet This study ...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarks on its Most Ambitious Hypertension Clinical Study Yet: HYPER-H21-4
12 Nov, 2021 FinancialContent
Lexaria Expands 2022 R&D Programs to Evaluate Alzheimer's, Diabetes
11 Nov, 2021 FinancialContent

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, today announced its plans for several new and ongoing ...

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands 2022 R&D Programs to Evaluate Potential Treatment Options for Alzheimer’s and Diabetes
10 Nov, 2021 FinancialContent
Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
10 Nov, 2021 FinancialContent
Lexaria Bioscience Corp. Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology's Efficacy in Reducing/Inhibiting Seizure Activity
04 Nov, 2021 FinancialContent

Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD has similar or ...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology’s Efficacy in Reducing/Inhibiting Seizure Activity; Strengthens IP Portfolio
03 Nov, 2021 FinancialContent
Lexaria Bioscience Corp. to Expand Hypertension Clinical Program Through Most Ambitious Study to Date
03 Nov, 2021 FinancialContent

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, today announced a significant new study to expand its ...

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date
03 Nov, 2021 FinancialContent
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
03 Nov, 2021 FinancialContent

Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market ...

Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4
03 Nov, 2021 FinancialContent
Lexaria Bioscience Corp. Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex
02 Nov, 2021 FinancialContent

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has begun a new study, EPIL-A21-1, designed to ...

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex
01 Nov, 2021 FinancialContent
Lexaria Announces DehydraTECH-CBD Versus Prescription CBD Program In Treating Seizures
01 Nov, 2021 FinancialContent

Lexaria Bioscience Corp(NASDAQ: LEXX) hascommenced a new study to comparethe effectiveness of Epidiolex to ...

Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
01 Nov, 2021 FinancialContent
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Earns Coverage for DehydraTECH(TM)’s Potential Market Reach, Multiple Uses
29 Oct, 2021 FinancialContent
Lexaria Bioscience Corp.'s DehydraTECH(TM) Addresses the Needs of Medical THC Users
26 Oct, 2021 FinancialContent

Lexaria’s THC absorption animal study yielded promising results on the patented DehydraTECH(TM) technology It showed that ...

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Addresses the Needs of Medical THC Users
26 Oct, 2021 FinancialContent
New Study Underscores Rapidity of Oral Drug Bio-delivery Using Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology as an Alternative to Smoking and Vaping
22 Oct, 2021 FinancialContent
New Study Underscores Rapidity of Oral Drug Bio-delivery Using Lexaria Bioscience Corp.'s Technology as an Alternative to Smoking and Vaping
22 Oct, 2021 Yahoo! Finance

Oral drug delivery innovator Lexaria Bioscience is focused on providing alternatives to smoked or inhaled tobacco and cannabis products to help consumers reduce the threat to their lungs Lexaria’s patented technology — DehydraTECH(TM) — is a solution that processes active pharmaceutical ingredients into a powder or liquid form that can then be ingested with less harm than inhalation, while providing rapidity similar to inhalation substances DehydraTECH has previously shown the ability to move CB

Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to Revolutionizing the Nicotine Industry with its Alternative Nicotine Delivery
20 Oct, 2021 FinancialContent
Lexaria Bioscience Corp.'s DehydraTECH(TM) Impacting the Pharmaceutical Industry
20 Oct, 2021 Yahoo! Finance

Lexaria Bioscience Corp. (NASDAQ: LEXX) has remained committed to enhancing the speed and overall efficiency of orally delivered fat-soluble active molecules. The company is leveraging its drug delivery technology, DehydraTECH(TM), in the development of hypertension and anti-viral treatments — a big achievement already making an impact in the pharmaceutical industry. “Since Lexaria began working on this technology in 2014, DehydraTECH has developed considerably and impacted the industry. So far,

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Study Reveals Effectiveness of Proprietary Drug-Development Tech
20 Oct, 2021 FinancialContent

Lexaria Bioscience Corp (LEXX) is a NASDAQ Common Stock listed in , ,

970x250